Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
RESEARCH TOOLSreports
Holding DE:9IP1?
Track your performance easily
9IP1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€11.71 - €29.42
Previous Close€14.3
Volume30.00
Average Volume (3M)40.00
Market Cap
€1.23B
Enterprise Value€1.03B
Total Cash (Recent Filing)$235.66M
Total Debt (Recent Filing)$25.64M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 06, 2025EPS Estimate
-€0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding91,157,085
10 Day Avg. Volume0
30 Day Avg. Volume40
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-447.54
Enterprise Value/Ebitda-4.10
Forecast
1Y Price Target
€44.88Price Target Upside213.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Rocket Pharmaceuticals News
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Danon Disease and PKD Studies
Bulls Say, Bears Say
Bulls Say
Clinical TrialsUpdated long-term data for RP-A501 in Danon disease shows all evaluable patients remain alive and transplant-free, indicating a promising advancement in treatment efficacy.
Regulatory AlignmentAlignment with the FDA on pivotal Phase 2 study endpoints for RP-A501 boosts confidence in regulatory approval and commercial potential.
Therapeutic AdvancementsRP-A501 demonstrated significant improvements in heart health metrics, suggesting it could redefine therapy for Danon disease by altering disease progression and preserving cardiac health.
Bears Say
Clinical TrialsInitiation of RP-L301's pivotal study has been delayed until 2025.
Financial PerformanceBalance sheet health is a key bear thesis, and timely PRV sale tied to Kresladi approval will be key to bridging to Danon launch.
Regulatory ApprovalRCKT announced slight delays to Kresladi, with approval now expected in 2025.
---
9IP1 FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was €11.71 and its highest was €29.42 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Currently, no data Available
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 99 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -€0.677 earnings per share for the quarter, beating the consensus estimate of -€0.715 by €0.038.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -€0.7.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 91,157,080 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -€0.677 in its last earnings report, beating expectations of -€0.715. Following the earnings report the stock price went down -2.376%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 76M.
---
Rocket Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€44.88 (213.94% Upside)
€44.88 (213.94% Upside)
Blogger Sentiment
Bullish
DE:9IP1 Sentiment 66%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $302.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.62%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
-34.25%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
9IP1 Stock 12 Month Forecast
Average Price Target
€44.88
▲(213.94% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Sangamo Biosciences
―
Best Analysts Covering 9IP1
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+15.32%
reiterated a buy rating 8 days ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +15.32% per trade.
---